Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2026; 17(1): 113463
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.113463
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.113463
Patients’ perception of proton pump inhibitors use and their risks
Ibrahim O Sawaied, Abraham O Samson, Azrieli Faculty of Medicine, Bar-Ilan University, Safed 2170000, Israel
Efrat Golan, Department of Pediatric Medicine, Haemek Hospital, Afula 2170000, Israel
Author contributions: Sawaid IO, Samson AO, and Golan E designed the research study; Sawaid IO and Golan E performed the research; Sawaid IO analyzed the data and drafted the manuscript; Samson AO critically revised the manuscript and supervised the project; All authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Human Subjects Institutional Review Board at Bar-Ilan University, Ramat Gan, Israel (Approval No. 300625649).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Technical appendix, statistical code, and anonymized dataset are available from the corresponding author at ibomsa13@gmail.com. All data have been de-identified to protect participant confidentiality.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ibrahim O Sawaied, Azrieli Faculty of Medicine, Bar-Ilan University, Henrietta Szold Street 8, Safed 2170000, Israel. ibomsa13@gmail.com
Received: August 26, 2025
Revised: September 15, 2025
Accepted: December 23, 2025
Published online: January 24, 2026
Processing time: 147 Days and 15.8 Hours
Revised: September 15, 2025
Accepted: December 23, 2025
Published online: January 24, 2026
Processing time: 147 Days and 15.8 Hours
Core Tip
Core Tip: This study is among the largest cross-sectional surveys of proton pump inhibitor users, involving 3000 patients across Israel. We found that most patients are unaware of the risks associated with long-term proton pump inhibitor therapy, including the potential link to gastric cancer. Despite lansoprazole showing a safer profile and greater improvements in quality of life, it remains underutilized compared with omeprazole and esomeprazole. Family support emerged as a protective factor, encouraging deprescribing attempts and improving patient outcomes. These findings highlight the need for better patient education, risk communication, and alignment of prescribing practices with current clinical evidence.